Galmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price

Dow Jones09-19

By Josh Beckerman

Galmed Pharmaceuticals shares fell 53% to $7.09 Wednesday after a massive surge on heavy volume Tuesday.

The company said in a Monday securities filing that it regained compliance with Nasdaq's $1 bid price requirement. After Monday's close of $3.87, shares closed at $15.10 the next day on volume of over 98.5 million shares, compared with a 90-day average of about 1.1 million shares.

Galmed is developing Aramchol for liver and fibro-inflammatory diseases.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

September 18, 2024 13:37 ET (17:37 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468537836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-19 01:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468537836","market":"hk","top_or_hot":-1,"title":"Galmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Galmed Pharmaceuticals shares fell 53% to $7.09 Wednesday after a massive surge on heavy volume Tuesday. \n</p>\n<p>\n  The company said in a Monday securities filing that it regained compliance with Nasdaq's $1 bid price requirement. After Monday's close of $3.87, shares closed at $15.10 the next day on volume of over 98.5 million shares, compared with a 90-day average of about 1.1 million shares. \n</p>\n<p>\n  Galmed is developing Aramchol for liver and fibro-inflammatory diseases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 18, 2024 13:37 ET (17:37 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 01:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n \n\n\n  Galmed Pharmaceuticals shares fell 53% to $7.09 Wednesday after a massive surge on heavy volume Tuesday. \n\n\n  The company said in a Monday securities filing that it regained...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2468537836","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468537836","pubTimestamp":1726681020,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Galmed Pharmaceuticals shares fell 53% to $7.09 Wednesday after a massive surge on heavy volume Tuesday.The company said in a Monday securities filing that it regained compliance with Nasdaq's $1 bid price requirement. After Monday's close of $3.87, shares closed at $15.10 the next day on volume of over 98.5 million shares, compared with a 90-day average of about 1.1 million shares.Galmed is developing Aramchol for liver and fibro-inflammatory diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GLMD":"Galmed Pharmaceuticals Ltd."},"translate_title":"Galmed Pharmaceuticals下跌53%，但仍远高于周一收盘价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLMD":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Galmed Pharmaceuticals shares fell 53% to $7.09 Wednesday after a massive surge on heavy volume Tuesday. \n\n\n  The company said in a Monday securities filing that it regained compliance with Nasdaq's $1 bid price requirement. After Monday's close of $3.87, shares closed at $15.10 the next day on volume of over 98.5 million shares, compared with a 90-day average of about 1.1 million shares. \n\n\n  Galmed is developing Aramchol for liver and fibro-inflammatory diseases. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 18, 2024 13:37 ET (17:37 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468537836"}